• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Akanda Corp.

    3/11/25 8:00:23 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AKAN alert in real time by email
    6-K 1 ea0233851-6k_akanda.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

    Commission File Number:  001-41324

     

    AKANDA CORP.

    (Name of registrant)

     

    1a, 1b Learoyd Road 

    New Romney TN28 8XU, United Kingdom 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    ☒   Form 20-F          ☐   Form 40-F

     

     

     

     

     

    First Towers & Fibers Corp.

     

    On March 5, 2025, Akanda Corp. (the “Company”) entered into a Share Exchange Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “SEA”), dated as of March 5, 2025, with First Towers & Fibers Corp., a corporation existing under the laws of the Province of British Columbia (“FTFC”) and the common shareholders of FTFC (the “Shareholders”). Subject to the terms and conditions set forth in the SEA, the parties will enter into a business combination transaction (the “Business Combination”), pursuant to which, among other things, all of the common shares of FTFC (the “Exchanged Shares”) shall be exchanged for either common shares, no par value, of the Company (the “Purchaser Shares”), or cash, and FTFC shall continuing as a wholly owned subsidiary of the Company.

     

    FTFC is a private company that develops, constructs and owns telecommunications infrastructure in Mexico. The Company and FTFC have previously entered into and announced a non-binding letter of intent with respect to the Business Combination which set out the basic terms and conditions of the Business Combination. A co-founder, shareholder, executive and director of FTFC is Christopher Cooper, a director of the Company. The Company can give no assurance when or if the Business Combination will be consummated.

     

    Substantially all of the Shareholders will receive consideration equal to one Purchaser Share for every 2.5 Exchanged Shares held immediately prior to the closing so exchanged in the Business Combination, or an aggregate of approximately 15.3 million Purchaser Shares, subject to adjustment as described in the SEA, including adjustments as a result of any reverse stock split or consolidation of the Purchaser Shares. The remaining Shareholders will instead receive as consideration an aggregate of US$14.1 million, payable by the Company 18 months after the closing of the Business Combination. The Company also agreed to assume outstanding options granted by FTFC and certain indebtedness of FTFC.

     

    Within three business days of the execution date, the Company shall advance to FTFC a $1.0 million loan on the same terms as the Company’s November 21, 2024 Bridge Loan Agreement with FTFC, pursuant to which the Company loaned to FTFC US$350,000 (the “Loan Agreement”). As a result of entering into the Loan Agreement and the SEA, Mr. Cooper should not be deemed an independent director of the Company under applicable Nasdaq continued listing requirements, and accordingly the Company does not have a majority of independent directors on its Board and Mr. Cooper [is expected to][has] resign from the Company’s Audit Committee, Compensation Committee and Nominating Committee.

     

    The SEA contains customary representations and warranties of the parties thereto with respect to the parties, the transactions contemplated by the SEA and their respective business operations and activities. The representations and warranties in the SEA shall terminate and expire upon the occurrence of the closing of the Business Combination.

     

    The SEA contains covenants of the parties thereto, including: (a) the requirement to take all reasonable steps to consummate the Business Combination, (b) preparation and filing of a Registration Statement on Form F-4 with respect to the Purchaser Shares issuable in connection with the Business Combination; (c) restrictions on the conduct of the Company’s and FTFC’s respective businesses; (d) to submit a listing application to Nasdaq for the combined company and to cause the Purchaser Shares to be approved for listing; and (e) the requirement that the Company shall file a non-offering prospectus with the Ontario Securities Commission in order for the Company to become a reporting issuer in the Province of Ontario.

     

    Consummation of the Business Combination is subject to conditions, including, among others: (a) there being no order, temporary restraining order, preliminary or permanent injunction, decree or ruling issued by a court of competent jurisdiction or governmental authority, enjoining, restraining or otherwise imposing a legal restraint on the consummation of the closing; (b) approval by the Company’s shareholders of certain proposals to be set forth in the Form F-4, including a reverse stock split or consolidation; (c) the Purchaser Shares to be issued pursuant to the SEA being approved for listing on the Nasdaq Capital Market and Nasdaq approving the listing of the post-Business Combination company; (d) the repayment, satisfaction and/or recapitalization of certain existing indebtedness of FTFC; (e) the Company shall have received a fairness opinion from a reputable valuation firm or investment bank expert in preparing fairness opinions for transactions similar to the Business Combination, showing that FTFC is valued at a price of at least US$19 million; (f) FTFC shall have delivered audited financial statements in accordance with IFRS to the Company as required by applicable rules of the Securities and Exchange Commission; and (g) the Form F-4 containing the Prospectus being declared effective in accordance with the provisions of the Securities Act of 1933, as amended (the “Securities Act”).

     

    1

     

     

    The SEA may be terminated under certain customary and limited circumstances, including (a) by mutual written consent of the Company and FTFC, (b) by either the Company or FTFC if the closing has not been consummated by March 31, 2025 as it may be extended, (c) by either the Company or FTFC, as applicable, in each instance that the other party materially breaches the SEA, or (d) by either the Company or FTFC if any permanent injunction or other order of a court or other competent authority preventing the closing of the Business Combination shall have become final and non-appealable. Upon termination of the SEA for any reason, the amounts loaned by the Company to FTFC shall be deemed immediately repayable.

     

    Following the closing of the Business Combination, the Company agreed to use commercially reasonable efforts to raise additional funds of at least $4.0 million and a maximum of $10.0 million compromising of: (i) a debt or equity financing by the Company of at least $2.0 million and a maximum $5.0 million within four months of the closing date; and (ii) a subsequent debt or equity financing to raise an additional amount of at least $2,000,000 and a maximum of $5,000,000 within seven months of the closing date, of which the type of securities offered and offering price will be determined in the context of the market by the Company.

     

    A copy of the SEA is filed with this Form 6-K as Exhibit 99.1, and the foregoing description of the SEA is qualified in its entirety by reference thereto.

     

    Cessation of Canmart Business

     

    After evaluating the current state of the Company’s business of importing and distributing cannabis-based products in the United Kingdom through its Canmart Ltd. subsidiary, the Company’s Board of Directors has determined to discontinue and cease its U.K operations and shut down Canmart Ltd. The Board came to this conclusion after receiving notification from Canmart’s directors that they intend to resign and the difficulty in finding qualified replacements, determining that the expense and timing of renewing its license to operate in the U.K. when compared to projected near-term future revenues is not cost effective, and evaluating the continued potential exposure to Canmart’s existing lawsuits, among other things.

     

    The Company reaffirms its commitment to continue its focus on the growth of its pre-revenue Canadian farming property in British Columbia, at which the Company plans to develop THC and CBD facilities. To date, the Company has not yet cultivated any product from this land.

     

    Press Release

     

    On March 10, 2025, the Company issued a press release announcing the execution of the SEA and the cessation of its Canmart business. A copy of the press release is furnished herewith as Exhibit 99.2 and incorporated herein by reference.

     

    Important Information and Where to Find It

     

    In connection with the proposed Business Combination, a registration statement on Form F-4 (the “Form F-4”) is expected to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Upon the closing of the Business Combination, it is expected that the Company will be the ultimate parent of FTFC. The Form F-4 will include a prospectus relating to the offer and sale of securities to be issued in connection with the completion of the Transaction. It may also include, if necessary, a preliminary proxy statement/ to be distributed to holders of the Company’s common shares in connection with its solicitation of proxies for the vote of its stockholders in connection with the matters relating to the Business Combination and other matters as described in the Form F-4. This document does not contain all the information that should be considered concerning the Business Combination or any other matter and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination or any other matter. The Company and FTFC urge investors, stockholders, shareholders and other interested persons to read, when available, the Form F-4, including the prospectus (and, if necessary, the proxy statement) included therein and the amendments thereto as well as any other documents filed with the SEC in connection with the Business Combination as these materials will contain important information about the Company, FTFC and the Business Combination. After the Form F-4 has been filed and declared effective, if applicable, the definitive proxy statement will be mailed to the Company’s stockholders as of the record date established for voting on the matters set forth therein. The Company and FTFC stockholders will be able to obtain copies of such documents, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Akanda Corp., c/o Gowling WLG, 100 King St. W, Suite 1600, Toronto, ON M5X 1G5.

     

    INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED THEREIN.

     

    2

     

     

    Participants in the Solicitation of Proxies

     

    This communication is not a solicitation of a proxy from any investor or securityholder. The Company, FTFC, and their respective directors, executive officers and other members of their management and employees, may, under SEC rules, be deemed to be participants in the solicitation of proxies of the Company’s stockholders in connection with the Business Combination. Investors and securityholders may obtain more detailed information regarding the names, affiliations and interests of the Company’s directors and executive officers in the Company’s Annual Report on Form 20-F filed with the SEC on May 1, 2024, and other reports filed with the SEC. Additional information regarding the participants will also be included in the Form F-4, when it becomes available. When available, these documents can be obtained free of charge from the sources indicated above.

     

    No Offer or Solicitation

     

    No offer or offering of equity interests or securities of any kind is being made, conducted or extended at this time. This communication is for informational purposes only and does not constitute or include an offer to sell, or a solicitation of an offer to purchase or subscribe for, equity interests or securities of any kind or a solicitation of any vote of approval, nor shall there be any sale, issuance or transfer of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Any such offer or solicitation will be made only in connection with the delivery of a prospectus meeting the requirements of the Securities Act, or exemptions therefrom.

     

    Forward-Looking Statements

     

    This Report on Form 6-K contains “forward-looking statements.” Such statements which are not purely historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “intends,” “would,” “could” and “estimates”) are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, the consummation of the Business Combination.

     

    Important factors, among others, that may affect actual results or outcomes include: (i) changes in domestic and foreign business, market, financial, political and legal conditions; (ii) the inability of the Company and FTFC to successfully or timely consummate the proposed Business Combination, including the risk that any required approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed Business Combination or that the approval of the stockholders of the Company and FTFC is not obtained; (iii) failure to realize the anticipated benefits of the proposed Business Combination; (iv) the limited operating history of each of the Company and FTFC; (v) the ability of each of the Company and FTFC to grow and manage its growth effectively; (vi) the ability of each of the Company and FTFC to execute their respective business plan; (vii) estimates of the size of the markets for their respective products; (viii) the rate and degree of market acceptance of their respective products; (ix) the Company’s ability to identify and integrate acquisitions; (x) future investments in technology and operations; (xi) potential litigation involving the Company or FTFC; (xii) risks relating to the uncertainty of the projected financial information with respect to FTFC; (xiii) the effects of competition on FTFC’s business; (xiv) developments and changes in laws and regulations; (xv) the impact of significant investigative, regulatory or legal proceedings; (xvi) general economic and market conditions impacting demand for either party’s products and services; (xvii) the ability to meet Nasdaq’s listing standards prior to and following the consummation of the proposed Business Combination; (xviii) the ability the Company or the combined company to issue equity or equity-linked securities in connection with the proposed Business Combination or in the future; and (xix) such other risks and uncertainties as are discussed in the Company’s Annual Report on Form 20-F filed with the SEC and the Form F-4 to be filed relating to the proposed Business Combination. Other factors include the possibility that the proposed Business Combination does not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

     

    Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 6-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 6-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from time-to-time with the Securities and Exchange Commission.

     

    Exhibit Number   Description
    99.1   Share Exchange Agreement dated as of March 5, 2025
    99.2   Press Release dated March 10, 2025

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      AKANDA CORP.
      (Registrant)
         
    Date:  March 10, 2025 By: /s/ Katie Field
        Name:  Katie Field
        Title: Interim Chief Executive Officer and Director

     

    4

    Get the next $AKAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKAN
    SEC Filings

    See more
    • SEC Form 6-K filed by Akanda Corp.

      6-K - AKANDA CORP. (0001888014) (Filer)

      5/1/25 5:00:02 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 20-F filed by Akanda Corp.

      20-F - AKANDA CORP. (0001888014) (Filer)

      4/30/25 3:00:22 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Akanda Corp.

      6-K - AKANDA CORP. (0001888014) (Filer)

      4/18/25 1:46:03 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Univest Securities, LLC Announces Closing of $5 Million Underwritten Public Offering for its Client Akanda Corp. (NASDAQ: AKAN)

      New York, March 27, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of underwritten public offering (the "Offering") of 3,087,443 common stock priced at $0.1217 per share, with pre-funded warrants exercisable for 37,997,190 shares with respect to the underwritten public offering for its client Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company"), an international medical cannabis company. Under the terms of the securities purchase agreement, the Company has agreed to sell to the institutional investors a total of 3,087,443 sh

      3/27/24 4:45:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Akanda Corp. Announces Signing of Option to Develop Canadian THC and CBD Farming Facility

      International medical cannabis company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN, WKN: A3DG83))) announces that Akanda (the "Optionee" the "Company") and 1107385 B.C. LTD (the "Owner") have agreed upon terms to purchase farming land and related operations and licenses. The key deal terms are as follows: Akanda will issue a non-refundable payment equal to One Million Eight Hundred Thousand United States Dollars (USD1,800,000) and if paid in common shares of Akanda will be based on formula to calculate the per share price as set forth in the agreement. The initial payment will be broken up into the First Option Payment, the Second Option Payment and the Third Option Payment, u

      9/20/23 9:00:00 AM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Akanda Corp. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

      International medical cannabis platform company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN) today announced that the Company has received a written notification (the "Notification Letter") on July 3, 2023 from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value ("Common Shares"), was below $1.00 per share for a period of 30 consecutive business days. The Notification Letter does not impact the Company's listing on the

      7/6/23 4:18:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Halo Collective Announces Change of Auditors and Failure to File Cease Trade Order

      Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Halo Collective Inc. (NEO: HALO) (OTCQB:HCANF) (FSE: A9K0) ("Halo" or the "Company") announces today that it has changed its auditor (the "Change of Auditor") from Macias Gini & O'Connell LLP (the "Former Auditor") to GreenGrowth CPAs (the "Successor Auditor"). The Former Auditor resigned effective June 19, 2023, and the Company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.There was no modified opinion, or other opinion, issued by the Former Auditor in connection with its audit of the Co

      6/22/23 1:06:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canmart Ends CEO Service Agreement; Akanda Approves Appointment of Director

      International medical cannabis platform company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk's Service Agreement dated June 2, 2021 (the "Service Agreement") to an immediate end with effect from February 13th, 2023. As disclosed on February 7th, 2023, the Company disclosed Mr. Virk's attempt to end the Service Agreement without providing the requisite period of notice required under the Service Agreement, his interpretation of the Service Agreement, and allegations of Breach of Contract. On February 13th, 2023, the Company informed Mr. Virk that it had reached the conclusion that it has a right to bring the Service

      2/16/23 5:05:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • /R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/

      TORONTO, Aug. 12, 2022 /PRNewswire/ -  Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced the appointment of Katie Field, Chief Executive Officer of Halo, to Chairman of the board of directors of the Company (the "Board"), effective immediately. Current Chairman Ryan Kunkel has resigned from the Board to focus on other professional endeavors. To the knowledge of the Company, Ms. Field is the second woman to serve as Chairman and CEO of a publicly traded cannabis company, the first being Kim Rivers of Trulieve (CSE:TRUL). Ca

      8/12/22 8:00:00 AM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Akanda Corp. (Amendment)

      SC 13D/A - AKANDA CORP. (0001888014) (Subject)

      2/20/24 6:01:03 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Akanda Corp.

      SC 13D - AKANDA CORP. (0001888014) (Subject)

      2/20/24 5:17:13 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Akanda Corp. (Amendment)

      SC 13G/A - AKANDA CORP. (0001888014) (Subject)

      2/20/24 12:55:32 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    Financials

    Live finance-specific insights

    See more
    • Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon

      TORONTO, Sept. 22, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced, further to its press release dated August 27, 2021, that it has completed the acquisition of all of the substantial assets of three operating entities doing business as Pistil Point in Oregon which collectively hold multiple cannabis licenses. With this transaction, Halo now has full ownership of a range of indoor and outdoor cultivation, manufacturing, and distributions assets, along with an expanded library of genetics that is expected to allow the Company to continue to execute its vertically integrated strategy in Oregon with enhanced compet

      9/22/22 5:00:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Halo Collective Announces Westwood Dispensary Completion, Local Inspections Passed, and Planned Opening for Second Budega™ in California

      TORONTO, April 12, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced that its Budega Westwood Dispensary passed its Los Angeles inspection and is expected to open within 30 days. The Budega Westwood location is perfectly located nestled in between Westwood to the west and Beverly Hills to the east, right off of one of LA's most traveled and famous thoroughfares for locals and visitors, the Santa Monica Boulevard (10461 Santa Monica Blvd) and within two miles of the University of Los Angeles California campus. The facility is leased and near complete with renovations of its approximately 1,500 square foot prime retail

      4/12/22 4:40:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care